Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Therapeutic Mechanisms of Shenyan Oral Liquid I Against Chronic Kidney Disease Based on Network Pharmacology and Experimental Validation

Author(s): Xudong Cheng, Guoqiang Liang, Min Liu, Rujun Song, Lan Zhou, Yan Ren, Yuyu Huang, Weimin Jin and Chunbo Jiang*

Volume 27, Issue 19, 2024

Published on: 13 November, 2023

Page: [2885 - 2898] Pages: 14

DOI: 10.2174/0113862073260994231031070916

open access plus

Abstract

Background: Chronic Kidney Disease (CKD) leads to structural and functional abnormalities of the kidneys and seriously jeopardizes human health. Shenyan Oral Liquid (SOLI), a Chinese medicinal preparation, has been reported to protect podocytes in patients with chronic kidney disease (CKD).

Objective: The objective of this study is to investigate the mechanism of action of the Chinese medicinal preparation Senyan Oral Liquid (SOLI) in the treatment of CKD by protecting podocytes through network pharmacology technology and experimental validation.

Methods: Compounds of SOLI and targets of CKD disease were collected and screened. The SOLI network of bioactive compounds targeting CKD and the protein-protein interaction (PPI) network were constructed using Cytoscape software and the STRING online database. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the R software Cluster Profiler package. Molecular docking was performed using Autodock software to verify the binding ability of bioactive compounds and target genes. Subsequently, the potential mechanism of SOLI on CKD predicted by network pharmacological analysis was experimentally studied and verified in an adriamycin-induced nephropathy rat model.

Results: A total of 81 targets of SOLI components acting on CKD were identified. The results of the PPI analysis clarified that five key target genes (TNF, AKT1, IL6, VEGFA, and TP53) play a critical role in the treatment of CKD by SOLI. The GO analysis and KEGG enrichment analysis indicated that SOLI acts through multiple pathways, including the PI3K/AKT signaling pathway against CKD. Molecular docking showed that the main compounds of SOLI and five key genes had strong binding affinity. In a rat model of adriamycin-induced nephropathy, SOLI significantly ameliorated disease symptoms and improved renal histopathology. Mechanistic studies showed that SOLI upregulated the expression level of Nephrin, inhibited the PI3K/AKT pathway in renal tissues, and ultimately suppressed the activation of autophagy-related proteins in CKD.

Conclusion: SOLI exerted a renoprotective effect by regulating the Nephrin-PI3K/AKT autophagy signaling pathway, and these findings provide new ideas for the development of SOLI-based therapeutic approaches for CKD.

« Previous Next »
[1]
Nehus, E. Obesity and chronic kidney disease. Curr. Opin. Pediatr., 2018, 30(2), 241-246.
[http://dx.doi.org/10.1097/MOP.0000000000000586] [PMID: 29346138]
[2]
Ruiz-Ortega, M.; Rayego-Mateos, S.; Lamas, S.; Ortiz, A.; Rodrigues-Diez, R.R. Targeting the progression of chronic kidney disease. Nat. Rev. Nephrol., 2020, 16(5), 269-288.
[http://dx.doi.org/10.1038/s41581-019-0248-y] [PMID: 32060481]
[3]
Liu, Z.H. Nephrology in China. Nat. Rev. Nephrol., 2013, 9(9), 523-528.
[http://dx.doi.org/10.1038/nrneph.2013.146] [PMID: 23877587]
[4]
Saran, R.; Robinson, B.; Abbott, K.C.; Agodoa, L.Y.C.; Albertus, P.; Ayanian, J.; Balkrishnan, R.; Bragg-Gresham, J.; Cao, J.; Chen, J.L.T.; Cope, E.; Dharmarajan, S.; Dietrich, X.; Eckard, A.; Eggers, P.W.; Gaber, C.; Gillen, D.; Gipson, D.; Gu, H.; Hailpern, S.M.; Hall, Y.N.; Han, Y.; He, K.; Hebert, P.; Helmuth, M.; Herman, W.; Heung, M.; Hutton, D.; Jacobsen, S.J.; Ji, N.; Jin, Y.; Kalantar-Zadeh, K.; Kapke, A.; Katz, R.; Kovesdy, C.P.; Kurtz, V.; Lavallee, D.; Li, Y.; Lu, Y.; McCullough, K.; Molnar, M.Z.; Montez-Rath, M.; Morgenstern, H.; Mu, Q.; Mukhopadhyay, P.; Nallamothu, B.; Nguyen, D.V.; Norris, K.C.; O’Hare, A.M.; Obi, Y.; Pearson, J.; Pisoni, R.; Plattner, B.; Port, F.K.; Potukuchi, P.; Rao, P.; Ratkowiak, K.; Ravel, V.; Ray, D.; Rhee, C.M.; Schaubel, D.E.; Selewski, D.T.; Shaw, S.; Shi, J.; Shieu, M.; Sim, J.J.; Song, P.; Soohoo, M.; Steffick, D.; Streja, E.; Tamura, M.K.; Tentori, F.; Tilea, A.; Tong, L.; Turf, M.; Wang, D.; Wang, M.; Woodside, K.; Wyncott, A.; Xin, X.; Zeng, W.; Zepel, L.; Zhang, S.; Zho, H.; Hirth, R.A.; Shahinian, V. US renal data system 2016 annual data report: Epidemiology of kidney disease in the united states. Am. J. Kidney Dis., 2017, 69(3), A7-A8.
[http://dx.doi.org/10.1053/j.ajkd.2016.12.004] [PMID: 28236831]
[5]
Mallett, A.; Patel, C.; Salisbury, A.; Wang, Z.; Healy, H.; Hoy, W. The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet J. Rare Dis., 2014, 9, 98.
[http://dx.doi.org/10.1186/1750-1172-9-98]
[6]
Breyer, M.D.; Susztak, K. Developing treatments for chronic kidney disease in the 21st century. Semin. Nephrol., 2016, 36(6), 436-447.
[http://dx.doi.org/10.1016/j.semnephrol.2016.08.001] [PMID: 27987541]
[7]
Palmer, S.C.; Mavridis, D.; Navarese, E.; Craig, J.C.; Tonelli, M.; Salanti, G.; Wiebe, N.; Ruospo, M.; Wheeler, D.C.; Strippoli, G.F.M. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis. Lancet, 2015, 385(9982), 2047-2056.
[http://dx.doi.org/10.1016/S0140-6736(14)62459-4] [PMID: 26009228]
[8]
Zhong, Y.; Deng, Y.; Chen, Y.; Chuang, P.Y.; Cijiang, He. J. Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney Int., 2013, 84(6), 1108-1118.
[http://dx.doi.org/10.1038/ki.2013.276] [PMID: 23868014]
[9]
Li, X.; Wang, H. Chinese herbal medicine in the treatment of chronic kidney disease. Adv. Chronic Kidney Dis., 2005, 12(3), 276-281.
[http://dx.doi.org/10.1016/j.ackd.2005.03.007] [PMID: 16010642]
[10]
Zhong, Y.; Menon, M.C.; Deng, Y.; Chen, Y.; He, J.C. Recent advances in traditional chinese medicine for kidney disease. Am. J. Kidney Dis., 2015, 66(3), 513-522.
[http://dx.doi.org/10.1053/j.ajkd.2015.04.013] [PMID: 26015275]
[11]
Mao, W.; Yang, N.; Zhang, L.; Li, C.; Wu, Y.; Ouyang, W.; Xu, P.; Zou, C.; Pei, C.; Shi, W.; Zhan, J.; Yang, H.; Chen, H.; Wang, X.; Tian, Y.; Yuan, F.; Sun, W.; Xiong, G.; Chen, M.; Guan, J.; Tang, S.; Zhang, C.; Liu, Y.; Deng, Y.; Lin, Q.; Lu, F.; Hong, W.; Yang, A.; Fang, J.; Rao, J.; Wang, L.; Bao, K.; Lin, F.; Xu, Y.; Lu, Z.; Su, G. Bupi yishen formula versus losartan for non-diabetic stage 4 chronic kidney disease: A randomized controlled trial. Front. Pharmacol., 2020, 11, 627185.
[12]
Chen, Y.; Deng, Y.; Ni, Z.; Chen, N.; Chen, X.; Shi, W.; Zhan, Y.; Yuan, F.; Deng, W.; Zhong, Y. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: A multicenter randomized controlled clinical trial. Am. J. Kidney Dis., 2013, 62(6), 1068-1076.
[http://dx.doi.org/10.1053/j.ajkd.2013.05.005] [PMID: 23810688]
[13]
Jiang, C.B. Clinical study of Shenyan oral liquid I on 35 cases of chronic nephritis with spleen deficiency and damp heat syndrome. Jiangsu. J. Tradit. Chin. Med., 2015, 47(10), 3.
[14]
Jiang, C. B Shenyan No.1 prescription combined with western medicine in the treatment of nephrotic syndrome and its effect on coagulation indexes and immune function of patients. Shanxi. J. Tradit. Chin. Med., 2020, 41(12), 4.
[15]
Jiang, C.; Liang, G.; Ren, Y.; Xu, T.; Song, Y.; Jin, W. An UPLC-MS/MS method for simultaneous quantification of the components of shenyanyihao oral solution in rat plasma. BioMed Res. Int., 2020, 2020, 4769267.
[16]
Liang, G.Q.; Ji, J. Protective effect of Shenyan oral liquid I in adriamycin-induced nephropathy rats based on “Autophagy-inflammatory reaction. Tradit. Chin. Med., 2019, 37(11)
[17]
Zhang, W.; Huai, Y.; Miao, Z.; Qian, A.; Wang, Y. Systems pharmacology for investigation of the mechanisms of action of traditional chinese medicine in drug discovery. Front. Pharmacol., 2019, 10, 743.
[http://dx.doi.org/10.3389/fphar.2019.00743]
[18]
Luo, Y.; Li, D.; Liao, Y.; Cai, C.; Wu, Q.; Ke, H.; Liu, X.; Li, H.; Hong, H.; Xu, Y.; Wang, Q.; Fang, J.; Fang, S. Systems pharmacology approach to investigate the mechanism of kai-xin-san in Alzheimer’s Disease. Front. Pharmacol., 2020, 11, 381.
[http://dx.doi.org/10.3389/fphar.2020.00381]
[19]
Ren, Y. Research progress and challenges of network pharmacology in the field of traditional Chinese medicine. Chin. Tradit. Herbal Drugs, 2020, 51(18), 9.
[20]
Hopkins, A.L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4(11), 682-690.
[http://dx.doi.org/10.1038/nchembio.118] [PMID: 18936753]
[21]
Xu, X.; Zhang, W.; Huang, C.; Li, Y.; Yu, H.; Wang, Y.; Duan, J.; Ling, Y. A novel chemometric method for the prediction of human oral bioavailability. Int. J. Mol. Sci., 2012, 13(6), 6964-6982.
[http://dx.doi.org/10.3390/ijms13066964] [PMID: 22837674]
[22]
Liu, H.; Wang, J.; Zhou, W.; Wang, Y.; Yang, L. Systems approaches and polypharmacology for drug discovery from herbal medicines: An example using licorice. J. Ethnopharmacol., 2013, 146(3), 773-793.
[http://dx.doi.org/10.1016/j.jep.2013.02.004] [PMID: 23415946]
[23]
Wang, X.W.; Tian, R.M.; Yang, Y.Q.; Wang, K.; Li, E.N.; Han, X.D.; Bao, K.; Mao, W.; Xu, H.T.; Liu, B.; Xu, P. Tripterygium glycoside fraction n2 ameliorates adriamycin-induced nephrotic syndrome in rats by suppressing apoptosis. J. Ethnopharmacol., 2020, 257, 112789.
[http://dx.doi.org/10.1016/j.jep.2020.112789]
[24]
Jiang, C.B.; Wei, M.G.; Tu, Y.; Zhu, H.; Li, C.Q.; Jing, W.M.; Sun, W. Triptolide attenuates podocyte injury by regulating expression of miRNA-344b-3p and miRNA-30b-3p in rats with adriamycin-induced nephropathy. Evid. Based Complement. Alternat. Med., 2015, 2015, 107814.
[http://dx.doi.org/10.1155/2015/107814]
[25]
Yin, L.; Mao, Y.; Song, H.; Wang, Y.; Zhou, W.; Zhang, Z. Vincristine alleviates adriamycin-induced nephropathy through stabilizing actin cytoskeleton. Cell Biosci., 2017, 7(1)
[http://dx.doi.org/10.1186/s13578-016-0129-z]
[26]
Carbon, S.; Douglass, E.; Good, B.M.; Unni, D.R.; Harris, N.L.; Mungall, C.J.; Basu, S.; Chisholm, R.L.; Dodson, R.J.; Hartline, E.; Fey, P.; Thomas, P.D.; Albou, L-P.; Ebert, D.; Kesling, M.J.; Mi, H.; Muruganujan, A.; Huang, X.; Mushayahama, T.; LaBonte, S.A.; Siegele, D.A.; Antonazzo, G.; Attrill, H.; Brown, N.H.; Garapati, P.; Marygold, S.J.; Trovisco, V.; dos Santos, G.; Falls, K.; Tabone, C.; Zhou, P.; Goodman, J.L.; Strelets, V.B.; Thurmond, J.; Garmiri, P.; Ishtiaq, R.; Rodríguez-López, M.; Acencio, M.L.; Kuiper, M.; Lægreid, A.; Logie, C.; Lovering, R.C.; Kramarz, B.; Saverimuttu, S.C.C.; Pinheiro, S.M.; Gunn, H.; Su, R.; Thurlow, K.E.; Chibucos, M.; Giglio, M.; Nadendla, S.; Munro, J.; Jackson, R.; Duesbury, M.J.; Del-Toro, N.; Meldal, B.H.M.; Paneerselvam, K.; Perfetto, L.; Porras, P.; Orchard, S.; Shrivastava, A.; Chang, H-Y.; Finn, R.D.; Mitchell, A.L.; Rawlings, N.D.; Richardson, L.; Sangrador-Vegas, A.; Blake, J.A.; Christie, K.R.; Dolan, M.E.; Drabkin, H.J.; Hill, D.P.; Ni, L.; Sitnikov, D.M.; Harris, M.A.; Oliver, S.G.; Rutherford, K.; Wood, V.; Hayles, J.; Bähler, J.; Bolton, E.R.; De Pons, J.L.; Dwinell, M.R.; Hayman, G.T.; Kaldunski, M.L.; Kwitek, A.E.; Laulederkind, S.J.F.; Plasterer, C.; Tutaj, M.A.; Vedi, M.; Wang, S-J.; D’Eustachio, P.; Matthews, L.; Balhoff, J.P.; Aleksander, S.A.; Alexander, M.J.; Cherry, J.M.; Engel, S.R.; Gondwe, F.; Karra, K.; Miyasato, S.R.; Nash, R.S.; Simison, M.; Skrzypek, M.S.; Weng, S.; Wong, E.D.; Feuermann, M.; Gaudet, P.; Morgat, A.; Bakker, E.; Berardini, T.Z.; Reiser, L.; Subramaniam, S.; Huala, E.; Arighi, C.N.; Auchincloss, A.; Axelsen, K.; Argoud-Puy, G.; Bateman, A.; Blatter, M-C.; Boutet, E.; Bowler, E.; Breuza, L.; Bridge, A.; Britto, R.; Bye-A-Jee, H.; Casas, C.C.; Coudert, E.; Denny, P.; Estreicher, A.; Famiglietti, M.L.; Georghiou, G.; Gos, A.; Gruaz-Gumowski, N.; Hatton-Ellis, E.; Hulo, C.; Ignatchenko, A.; Jungo, F.; Laiho, K.; Le Mercier, P.; Lieberherr, D.; Lock, A.; Lussi, Y.; MacDougall, A.; Magrane, M.; Martin, M.J.; Masson, P.; Natale, D.A.; Hyka-Nouspikel, N.; Orchard, S.; Pedruzzi, I.; Pourcel, L.; Poux, S.; Pundir, S.; Rivoire, C.; Speretta, E.; Sundaram, S.; Tyagi, N.; Warner, K.; Zaru, R.; Wu, C.H.; Diehl, A.D.; Chan, J.N.; Grove, C.; Lee, R.Y.N.; Muller, H-M.; Raciti, D.; Van Auken, K.; Sternberg, P.W.; Berriman, M.; Paulini, M.; Howe, K.; Gao, S.; Wright, A.; Stein, L.; Howe, D.G.; Toro, S.; Westerfield, M.; Jaiswal, P.; Cooper, L.; Elser, J. The Gene Ontology resource: Enriching a Gold mine. Nucleic Acids Res., 2021, 49(D1), D325-D334.
[http://dx.doi.org/10.1093/nar/gkaa1113] [PMID: 33290552]
[27]
Kanehisa, M.; Sato, Y.; Kawashima, M.; Furumichi, M.; Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res., 2016, 44(D1), D457-D462.
[http://dx.doi.org/10.1093/nar/gkv1070] [PMID: 26476454]
[28]
Wang, Y.; Feng, Y.; Li, M.; Yang, M.; Shi, G.; Xuan, Z.; Yin, D.; Xu, F. Traditional chinese medicine in the treatment of chronic kidney diseases: Theories, applications, and mechanisms. Front. Pharmacol., 2022, 13, 917975.
[http://dx.doi.org/10.3389/fphar.2022.917975] [PMID: 35924053]
[29]
Qi, Z.Q. Application of dispelling discharge in the treatment of chronic kidney disease with damp-heat syndrome. Tradit. Chin. Med., 2018, 33(05), 4.
[30]
Kma, L.; Baruah, T.J. The interplay of ROS and the PI3K/Akt pathway in autophagy regulation. Biotechnol. Appl. Biochem., 2022, 69(1), 248-264.
[http://dx.doi.org/10.1002/bab.2104] [PMID: 33442914]
[31]
Yin, H.; Zuo, Z.; Yang, Z.; Guo, H.; Fang, J.; Cui, H.; Ouyang, P.; Chen, X.; Chen, J.; Geng, Y.; Chen, Z.; Huang, C.; Zhu, Y. Nickel induces autophagy via PI3K/AKT/mTOR and AMPK pathways in mouse kidney. Ecotoxicol. Environ. Saf., 2021, 223, 112583.
[32]
Inker, L.A.; Levey, A.S.; Coresh, J. Estimated glomerular filtration rate from a panel of filtration markers—hope for increased accuracy beyond measured glomerular filtration rate? Adv. Chronic Kidney Dis., 2018, 25(1), 67-75.
[http://dx.doi.org/10.1053/j.ackd.2017.10.004] [PMID: 29499889]
[33]
Patrakka, J.; Tryggvason, K. New insights into the role of podocytes in proteinuria. Nat. Rev. Nephrol., 2009, 5(8), 463-468.
[http://dx.doi.org/10.1038/nrneph.2009.108] [PMID: 19581907]
[34]
Matsusaka, T.; Sandgren, E.; Shintani, A.; Kon, V.; Pastan, I.; Fogo, A.B.; Ichikawa, I. Podocyte injury damages other podocytes. J. Am. Soc. Nephrol., 2011, 22(7), 1275-1285.
[http://dx.doi.org/10.1681/ASN.2010090963] [PMID: 21719786]
[35]
Sanajou, D.; Ghorbani Haghjo, A.; Argani, H.; Roshangar, L.; Ahmad, S.N.S.; Jigheh, Z.A.; Aslani, S.; Panah, F.; Rashedi, J.; Mesgari Abbasi, M. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats. J. Physiol. Biochem., 2018, 74(3), 467-478.
[http://dx.doi.org/10.1007/s13105-018-0640-2] [PMID: 29948786]
[36]
Yang, Z.; Klionsky, D.J. Eaten alive: A history of macroautophagy. Nat. Cell Biol., 2010, 12(9), 814-822.
[http://dx.doi.org/10.1038/ncb0910-814] [PMID: 20811353]
[37]
Asanuma, K.; Tanida, I.; Shirato, I.; Ueno, T.; Takahara, H.; Nishitani, T.; Kominami, E.; Tomino, Y. MAP‐LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis. FASEB J., 2003, 17(9), 1165-1167.
[http://dx.doi.org/10.1096/fj.02-0580fje] [PMID: 12709412]
[38]
Song, Z.; Guo, Y.; Zhou, M.; Zhang, X. The PI3K/p-Akt signaling pathway participates in calcitriol ameliorating podocyte injury in DN rats. Metabolism, 2014, 63(10), 1324-1333.
[http://dx.doi.org/10.1016/j.metabol.2014.06.013] [PMID: 25044177]
[39]
Liu, N.; Xu, L.; Shi, Y.; Zhuang, S. Podocyte autophagy: A potential therapeutic target to prevent the progression of diabetic nephropathy. J. Diabetes Res., 2017, 2017, 3560238.
[http://dx.doi.org/10.1155/2017/3560238]
[40]
Yu, Z.K.; Yang, B.; Zhang, Y.; Li, L.S.; Zhao, J.N.; Hao, W. Modified Huangqi Chifeng decoction inhibits excessive autophagy to protect against Doxorubicin induced nephrotic syndrome in rats via the PI3K/mTOR signaling pathway. Exp. Ther. Med., 2018, 16(3), 2490-2498.
[http://dx.doi.org/10.3892/etm.2018.6492] [PMID: 30210600]
[41]
Hemmings, B.A.; Restuccia, D.F. PI3K-PKB/Akt pathway. Cold Spring Harb. Perspect. Biol., 2012, 4(9), a011189.
[http://dx.doi.org/10.1101/cshperspect.a011189] [PMID: 22952397]
[42]
Yu, S.; Ren, Q.; Chen, J.; Huang, J.; Liang, R. Rapamycin reduces podocyte damage by inhibiting the PI3K/AKT/mTOR signaling pathway and promoting autophagy. Eur. J. Inflamm., 2022, 20, 1721727X221081732.
[43]
Huber, T.B.; Hartleben, B.; Kim, J.; Schmidts, M.; Schermer, B.; Keil, A.; Egger, L.; Lecha, R.L.; Borner, C.; Pavenstädt, H.; Shaw, A.S.; Walz, G.; Benzing, T. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol. Cell. Biol., 2003, 23(14), 4917-4928.
[http://dx.doi.org/10.1128/MCB.23.14.4917-4928.2003] [PMID: 12832477]
[44]
Lu, H.; Yao, H.; Zou, R.; Chen, X.; Xu, H. Galangin suppresses renal inflammation via the inhibition of NF-kappaB, PI3K/AKT and NLRP3 in uric acid treated NRK-52E tubular epithelial cells. BioMed Res. Int., 2019, 2019, 3018357.
[45]
Ni, W.J.; Zhou, H.; Ding, H.H.; Tang, L.Q. Berberine ameliorates renal impairment and inhibits podocyte dysfunction by targeting the phosphatidylinositol 3‐kinase–protein kinase B pathway in diabetic rats. J. Diabetes Investig., 2020, 11(2), 297-306.
[http://dx.doi.org/10.1111/jdi.13119] [PMID: 31336024]
[46]
Huber, T.B.; Köttgen, M.; Schilling, B.; Walz, G.; Benzing, T. Interaction with podocin facilitates nephrin signaling. J. Biol. Chem., 2001, 276(45), 41543-41546.
[http://dx.doi.org/10.1074/jbc.C100452200] [PMID: 11562357]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy